ClinicalTrials.gg
CompletedNCT06015373Updated Aug 29, 2023

The Impact of Carvedilol Posology on Clinically Significant Portal Hypertension

An interventional study of supress the night dose of carvedilol in Clinically Significant Portal Hypertension, sponsored by Centro Hospitalar De São João, E.P.E.. Completed at 1 site in Portugal. Open to participants aged 18 Years to 77 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-29.

Sponsored by Centro Hospitalar De São João, E.P.E. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years to 77 Years
Sex
All
01

Study summary

Carvedilol has emerged as the preferred non-selective β-blocker (NSBB) for treating portal hypertension. However, there is still a debate in dosing regimen, specially regarding dose interval, with a potential lower bioavalability in once daily regimens. The aim of this study is to assess the acute effects of carvedilol posology in patients with clinically significant portal hypertension (CSPH), as a surrogate marker of bioavailability.

In this experimental study, patients with CSPH receiving carvedilol twice daily were asked to supress the night dose of carvedilol, in order to have a dose interval of approximately 24 hours. Spleen stiffness measurement (SSM) by transient elastography (TE) was performed and compared with SSM prior or under treatment. Same procedure was applied to liver stiffness measurement (LSM).

02

Conditions studied

  • Clinically Significant Portal Hypertension

Browse trials for

Keywords

  • portal hypertension
  • carvedilol
  • elastography
03

In context

Hypertension, Portal

376 studies on the registry are indexed under Hypertension, Portal; 114 are open to participants now.

This study's enrollment of 34 is below the median of 60 across 232 interventional studies indexed under Hypertension, Portal.

Browse Hypertension, Portal studies →

Lead sponsor

Centro Hospitalar De São João, E.P.E. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with CSPH (defined as a LSM 25 kPa or SSM over 45kPa prior to introduction of carvedilol)

Exclusion criteria

Exclusion Criteria:

  • Non-responders to non-selective β-blockers (NSBB)
  • NSBB other than carvedilol
  • Dosing regimen other than twice daily
  • No SSM or LSM within 3 months prior to the beginning of the study
  • (BMI) > 30 m/kg2
  • to NSBB use
  • Portal venous thrombosis
  • Refusal to participate in the study
  • Failure to comply to the study regimen
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Patients with CSPH receiving carvedilol twice daily and supress the night dose of carvedilol

    In this experimental study, 34 patients with CSPH receiving carvedilol twice daily were asked to supress the night dose of carvedilol, in order to have a dose interval of approximately 24 hours. Spleen stiffness measurement (SSM) by transient elastography (TE) was performed and compared with SSM prior or under treatment. Same procedure was applied to liver stiffness measurement (LSM).

    Drug: supress the night dose of carvedilol

Interventions

  • Drugsupress the night dose of carvedilol

    already described

06

What researchers measure

Primary outcomes

  1. spleen stiffness measurement (SSM)

    Change from baseline in spleen stiffness measurement (SSM) measured by transient elastography (TE) after 24 hour suspension of carvedilol treatment.

    Time frame: Baseline SSM measured up to 3 months before enrolment, and measured at 24 hours after suspending carvedilol

Secondary outcomes

  1. liver stiffness measurement (LSM)

    Change from baseline in liver stiffness measurement (LSM) measured by transient elastography (TE) after 24 hour suspension of carvedilol treatment.

    Time frame: Baseline LSM measured up to 3 months before enrolment, and measured at 24 hours after suspending carvedilol

07

Study locations

1 site
  • Centro Hospitalar de Trás os Montes e Alto Douro
    Vila Real, Lordelo 5000-508, Portugal
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Jun 2023, 0 months.

Of 57 non-industry interventional studies with no phase under Hypertension, Portal, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 72. This study's 0 months is below that.

Counting every sponsor, half of 61 studies reached it within 41 months; a quarter within 19 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2023
First posted
Aug 29, 2023
StartActual
Jun 1, 2023
Primary completionActual
Jun 30, 2023
CompletionActual
Jul 31, 2023
Last update
Aug 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06015373
Lead sponsor
Centro Hospitalar De São João, E.P.E.
Responsible party
Bruno Besteiro (MD, Principal Investigator, Centro Hospitalar De São João, E.P.E.) — Principal investigator
First posted
Aug 29, 2023
Start date
Jun 1, 2023
Primary completion
Jun 30, 2023
Completion
Jul 31, 2023
Last update
Aug 29, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion